Arylazoamidoximes and related compounds as NO-modulators

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Biochemistry

Background:

• Nitric oxide (NO) is a critical signaling molecule involved in various physiological processes.
• Dysregulation of NO homeostasis is implicated in cardiovascular diseases and thrombosis.
• Development of novel NO modulators is essential for therapeutic interventions.

Purpose of the Study:

• To synthesize and investigate novel amidinoarylhydrazine, arylazoamidine, and arylazoamidoxime derivatives as potential nitric oxide (NO) modulators.
• To evaluate the in vitro and in vivo effects of these compounds on platelet aggregation, blood pressure, and NO biosynthesis pathways.

Main Methods:

• Synthesis of three classes of compounds: amidinoarylhydrazines (1), arylazoamidines (2), and arylazoamidoximes (3).
• In vitro assays for platelet aggregation inhibition and nitric oxide synthase (NOS) activity.
• In vivo studies in spontaneously hypertensive rats (SHR) for antihypertensive effects and in arterioles for thrombus formation inhibition.

Main Results:

• Arylazoamidines (2) and arylazoamidoximes (3) inhibited platelet aggregation in vitro and in vivo.
• Arylazoamidine (2a) demonstrated significant antihypertensive effects in SHR rats.
• Arylazoamidoximes (3) were found to be potent activators of NOS isoforms, increasing activity up to fivefold in the presence of L-arginine.

Conclusions:

• Novel classes of NO-modulating compounds, particularly arylazoamidoximes, show significant potential.
• Arylazoamidoximes (3) act as potent activators of NOS isoforms.
• Arylazoamidines (2) exhibit in vivo effects, including antiplatelet and antihypertensive actions, through mechanisms yet to be fully elucidated.